NDA 021014 · Novartis
Trileptal
Oxcarbazepine · Oral · Anti-epileptic Agent
NovelLast checked: Nov 19, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Jan 14, 2000
Approved uses
3
Original approval plus efficacy supplements
Registered trials
62
13 Phase 3, 2 recruiting
FAERS reports
31,740
24,137 serious, 2,192 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 28, 2026.
TRILEPTAL is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. TRILEPTAL is indicated for: Adults: Monotherapy or adjunctive therapy in the treatment of partial-onset seizures Pediatrics: - Monotherapy in the treatment of partial-onset seizures in children 4-16 years - Adjunctive therapy in the treatment of partial-onset seizures in children 2-16 years ( 1 )
Mechanism: The pharmacological activity of TRILEPTAL is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine [ see Clinical Pharmacology (12.3) ]. The precise mechanism by which oxcarbazepine and MHD exert their anti-seizure effect is unknown; however, in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. These actions are thought to be important in the prevention of...
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 28, 2005 Supplement 13 · Efficacy · priority review Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Statistical Review
- Aug 7, 2003 Supplement 3 · Efficacy ReviewLetterLabel
- Jan 14, 2000 Original approval · Type 1 - New Molecular Entity NovelReviewHealthcare Professional SheetLetter
3 products under this application
- TRILEPTAL · OXCARBAZEPINE 300MG · TABLET, ORAL · Prescription · TE AB
- TRILEPTAL · OXCARBAZEPINE 600MG · TABLET, ORAL · Prescription · TE AB
- TRILEPTAL · OXCARBAZEPINE 150MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Oxcarbazepine" as an intervention, any sponsor and status, largest first.
- Modality Choice Before and After Failure for the Treatment of Painful Diabetic NeuropathyPivotal-lookingNot yet recruiting
University of MichiganAcademic, hospital or other
NCT07795593 · 600 participants (planned) · Start Nov 2026 · Primary completion May 2031
Drug: Oral Medication; Topical Medication · For: Painful Diabetic Neuropathy (PDN); Diabetic Nephropathies
Sites: Stanford, California; Jacksonville, Florida; Chicago, Illinois · 23 sites in all
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
- Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial SeizuresPivotal-lookingCompleted
Supernus Pharmaceuticals, Inc.Industry
NCT00772603 · 366 participants · Start Nov 2008 · Primary completion Apr 2010
Drug: Placebo; 2400mg SPN-804 and 1 more · For: Epilepsies, Partial
Sites: Huntsville, Alabama; Northport, Alabama; Phoenix, Arizona · 71 sites in all
- Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial EpilepsyPivotal-lookingCompleted
Korea UCB Co., Ltd.Industry
NCT01498822 · 353 participants · Start Jun 2011 · Primary completion Jul 2014
Drug: Levetiracetam; Oxcarbazepine · For: Epilepsy
Sites: Busan, South Korea; Daejeon, South Korea; Gangwon-Do, South Korea · 23 sites in all
- Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial EpilepsyPivotal-lookingCompleted
Supernus Pharmaceuticals, Inc.Industry
NCT00908349 · 214 participants · Start Jun 2009 · Primary completion Nov 2011
Drug: Oxcarbazepine XR · For: Partial Epilepsy
Sites: Huntsville, Alabama; Northport, Alabama; Phoenix, Arizona · 58 sites in all
- Intervention Study for Individuals With Compulsive Sexual BehaviorPivotal-lookingCompleted
University of Sao Paulo General HospitalAcademic, hospital or other
NCT02300051 · 135 participants · Start Feb 2011 · Primary completion Apr 2015
Drug: TAU · For: Compulsive Sexual Behavior
Sites: São Paulo, Brazil
- Comparision Efficacy of Carbamazepine & Oxcarbazepine in the Treatment of Trigeminal Neuralgia- a Randomised Clinical TrialPivotal-lookingStatus unknown
Postgraduate Institute of Dental Sciences RohtakAcademic, hospital or other
NCT04996199 · 132 participants (planned) · Start Sep 18, 2021 · Primary completion Dec 31, 2021
Drug: Oxcarbazepine; Carbamazepine · For: Trigeminal Neuralgia
Sites: Rohtak, India · 2 sites in all
- Pediatric Epilepsy StudyPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00050934 · 132 participants · Start Jun 2002 · Primary completion Jun 2004
Drug: oxcarbazepine · For: Epilepsy; Epilepsies, Partial
Sites: Birmingham, Alabama; Mobile, Alabama; Los Angeles, California · 30 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2,931
- seizure2,829
- off label use1,726
- dizziness1,533
- fatigue1,465
- convulsion1,455
- nausea1,317
- headache1,301
- somnolence1,251
- fall1,208
- hyponatraemia1,183
- vomiting1,131
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 631 |
| 2005 | 749 |
| 2006 | 782 |
| 2007 | 779 |
| 2008 | 722 |
| 2009 | 1,057 |
| 2010 | 1,058 |
| 2011 | 1,110 |
| 2012 | 1,389 |
| 2013 | 1,153 |
| 2014 | 1,247 |
| 2015 | 1,809 |
| 2016 | 1,930 |
| 2017 | 1,761 |
| 2018 | 1,893 |
| 2019 | 1,919 |
| 2020 | 1,795 |
| 2021 | 1,803 |
| 2022 | 1,644 |
| 2023 | 1,758 |
| 2024 | 1,747 |
| 2025 | 1,711 |
| 2026 | 1,290 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Trileptal (Oxcarbazepine)
2024 spending
$19.4M
Beneficiaries
1,548
10,640 claims
Per beneficiary
$12,548
$11.79 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $21,734,725 |
| 2021 | $20,129,436 |
| 2022 | $20,037,373 |
| 2023 | $20,960,477 |
| 2024 | $19,424,100 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Vestibular paroxysmia: a systematic review.
Dieterich M, Brandt T · J Neurol 2025 · Systematic Review
- Drug-Induced Myoclonus: A Systematic Review.
Rissardo JP, Fornari Caprara AL, Bhal N, et al. · Medicina (Kaunas) 2025 · Systematic Review
- Epilepsy.
Marson AG, Maguire M, Ramaratnam S · BMJ Clin Evid 2009 · Systematic Review
- Pharmacotherapy of impulse control disorders: A systematic review.
Tahir T, Wong MM, Maaz M, et al. · Psychiatry Res 2022 · Systematic Review
- Review and Consensus on Pharmacogenomic Testing in Psychiatry.
Bousman CA, Bengesser SA, Aitchison KJ, et al. · Pharmacopsychiatry 2021 · Systematic Review, Consensus Statement
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.